Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

Phase 2

Not yet recruiting

• Conditions: Hodgkin Lymphoma
• Interventions: Drug: Pembrolizumab

• Registration Number: NCT06045195
• Lead Sponsor: University of Cologne

Brief Summary

The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-09-12
• Study First Submitted QC: 2023-09-19
• Study First Posted: 2023-09-21
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-02
• Last Update Posted: 2025-04-06
• Study Start: 2025-08
• Primary Completion: 2027-01
• Study Completion: 2029-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• age 18-60
• advanced stage classical Hodgkin Lymphoma
• no previous treatment for cHL

Main

Exclusion Criteria

• Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
• Chemotherapy or radiotherapy in medical history
• Prior or concurrent disease that prevents treatment according to protocol

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment	Pembrolizumab	Pembrolizumab + BrECADD

Primary Outcome Measures

Name	Time	Method
progression free survival	1 year

Trial Locations

Locations (1)

1st Department of Medicine, Cologne University Hospital; 🇩🇪 Cologne, Germany